Delta12-prostaglandinJ2-nano capsule up-regulates growth factor expression and enhances bone regeneration in rats.
- Author:
Lili CHEN
1
;
Fen WEI
1
;
Weilian SUN
1
;
Peihui DING
1
;
Xiaotao CHEN
1
;
Yanmin WU
2
;
Email: WYM731128@126.COM.
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Bone Morphogenetic Protein 6; genetics; metabolism; Bone Regeneration; drug effects; Ephrin-B2; genetics; metabolism; Femur; drug effects; surgery; Lactic Acid; pharmacokinetics; pharmacology; Male; Nanocapsules; administration & dosage; Nanoparticles; administration & dosage; Particle Size; Polyglycolic Acid; pharmacokinetics; pharmacology; Prostaglandin D2; pharmacokinetics; pharmacology; RNA, Messenger; metabolism; Random Allocation; Rats; Rats, Wistar; Receptor, Platelet-Derived Growth Factor beta; genetics; metabolism; Time Factors; Up-Regulation
- From: Chinese Journal of Stomatology 2015;50(3):151-156
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of local delivery of delta12-prostaglandinJ2-loaded poly (lactic-co-glycolic acid) (Δ(12)-PGJ2-NC) on growth factors expression and bone formation.
METHODSΔ(12)-PGJ2-NC was prepared by the emulsion solvent diffusion method. The physical and chemical properties of the nanoparticles were evaluated by particle size analysis, transmission electron microscopy, drug-loading ratio and the in vitro release study. Then standardized transcortical defect (5.0 mm × 1.5 mm) was conducted in the femur of 48 male Wistar rats which were randomly divided into four groups (n = 12), S, K, F, and N. Thirty microliter of saline (S), unloaded nanoparticles (K), Δ(12)-PGJ2 (F) and Δ(12)-PGJ2-NC(N) in a collagen vehicle were delivered inside a titanium chamber fixed over the defect. Then, four subgroups were randomly divided in each group named as D3, D7, D14, and D28 (n = 3) according to the days 3, 7, 14, and 28 after the surgery. At days 3, 7, 14, and 28, the mRNA expression of the bone morphogenetic protein-6 (BMP-6), platelet-derived growth factor-B (PDGF-B) in defect aera was analyzed by real time quantitive-polymerase blotting. HE staining was employed to reveal new bone formation in weeks 2 and 4.
RESULTSΔ(12)-PGJ2-NC appeared opalescent white and remained relatively stable, with an average particle size of (135.2 ± 0.85) nm. The images from transmission electron microscopy showed that Δ(12)-PGJ2-NC was spherical in shape and homogeneously distributed. The encapsulation efficiency of Δ(12)-PGJ2 with the poly (lactic-co-glycolic acid) (PLGA) nanocapsules was about 92%. The in vitro release of Δ(12)-PGJ2-NC at 37 °C showed a sustained fashion and the average accumulated amount was 30%, 52%, 77%, 91%, and 98% respectively, at 0.5, 1, 2, 4 and 6 h. Compared with the animals treated with saline, after dose of 100 mg/L Δ(12)-PGJ2 and Δ(12)-PGJ2-NC apllication, the mRNA expression level of BMP-6, PDGF-B increased significantly (P < 0.05, P < 0.001). The protein expression of BMP-6, Ephrin-B2 also was up-regulated. Histomorphometry revealed that new bone formation increased at the same dose of 100 mg/L. But the unloaded nanoparticles did not have the same effect (P > 0.05).
CONCLUSIONSA stable Δ(12)-PGJ2 loaded nanoparticle was successfully prepared. Δ(12)-PGJ2-NC may upregulate the expression of BMP-6, PDGF-B and Ephrin-B2, and promote new bone formation in bone defect area.